Erste Asset Management GmbH Sells 28,226 Shares of Bristol Myers Squibb Company $BMY

Erste Asset Management GmbH trimmed its stake in Bristol Myers Squibb Company (NYSE:BMY) by 34.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 54,391 shares of the biopharmaceutical company’s stock after selling 28,226 shares during the period. Erste Asset Management GmbH’s holdings in Bristol Myers Squibb were worth $2,943,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Physician Wealth Advisors Inc. grew its position in Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares during the last quarter. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb during the second quarter valued at approximately $25,000. EQ Wealth Advisors LLC bought a new position in Bristol Myers Squibb during the fourth quarter valued at approximately $32,000. Garner Asset Management Corp bought a new position in Bristol Myers Squibb during the fourth quarter valued at approximately $35,000. Finally, Beacon Financial Strategies CORP bought a new position in Bristol Myers Squibb during the fourth quarter valued at approximately $38,000. 76.41% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.05% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on BMY. HSBC increased their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday, March 17th. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Guggenheim restated a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Piper Sandler restated an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Finally, Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Stock Up 1.5%

Shares of Bristol Myers Squibb stock opened at $56.43 on Wednesday. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The stock has a market capitalization of $115.23 billion, a price-to-earnings ratio of 15.85, a P/E/G ratio of 0.16 and a beta of 0.24. The company’s 50 day moving average price is $57.98 and its 200-day moving average price is $56.73.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the firm posted $1.80 earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.